Black Diamond Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will present company updates at several upcoming investor conferences. Notable events include: the Cowen 41^st Annual Virtual Health Care Conference on March 2, 2021, the H.C. Wainwright Virtual Global Life Sciences Conference starting March 9, 2021, and the 10^th Annual J.P. Morgan Napa Valley Forum on March 31, 2021. Live webcasts and replays of these presentations will be available on the company's investor relations website.

CAMBRIDGE, Mass. and NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences:

• The Cowen 41^st Annual Virtual Health Care Conference. Dr. Epstein will be featured in a lung cancer panel session on Tuesday, March 2, 2021 at 11:10 AM ET. The session will be available via live webcast to conference attendees.
• H.C. Wainwright Virtual Global Life Sciences Conference. The presentation will be available on demand beginning Tuesday, March 9, 2021 at 7:00 AM ET.
• The 10^th Annual J.P. Morgan Napa Valley Forum. The presentation will take place on Wednesday, March 31, 2021 at 3:00 PM ET.
  

Webcasts of the H.C. Wainwright and J.P. Morgan presentations can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of each presentation will also be available and archived on the site for three weeks.

About Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com

FAQ

What is the date for Black Diamond Therapeutics' presentation at the Cowen Conference?

David M. Epstein, Ph.D. will present at the Cowen 41^st Annual Virtual Health Care Conference on March 2, 2021, at 11:10 AM ET.

When can I access the H.C. Wainwright Virtual Global Life Sciences Conference presentation by BDTX?

The presentation will be available on demand starting March 9, 2021, at 7:00 AM ET.

What is the schedule for the J.P. Morgan Napa Valley Forum presentation by BDTX?

The presentation will take place on March 31, 2021, at 3:00 PM ET.

Where can I watch the presentations from Black Diamond Therapeutics?

Webcasts of the presentations can be accessed in the investor relations section of Black Diamond Therapeutics' website.

What is the focus of Black Diamond Therapeutics?

Black Diamond Therapeutics specializes in precision oncology and develops small molecule, tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers.